CAS No.: 1358751-06-0
Product introduction:TAK-653 (also known as Osavampator or NBI-1065845) is a novel, orally active positive allosteric modulator of AMPA receptors developed by Takeda Pharmaceutical Company for the treatment of major depressive disorder, particularly in patients with inadequate response to standard therapies. Unlike traditional AMPA receptor modulators, TAK-653 is characterized by exceptionally low agonist activity, which may help circumvent common side effects such as convulsions or psychotomimetic symptoms. By precisely enhancing AMPA receptor signaling driven by physiologically released glutamate, this compound aims to offer a safer pharmacological strategy. It has completed Phase 2 clinical trials for depression and is also being investigated for cognitive impairment associated with schizophrenia.
CAS No.:1358751-06-0
TAK-653 is a yellow to off-white solid powder with a molecular weight of 373.47 and the molecular formula C₁₉H₂₃N₃O₃S. It acts as a highly selective positive allosteric modulator of AMPA receptors, binding in a glutamate-dependent manner and exhibiting virtually no direct agonistic activity. This mechanism facilitates calcium influx and enhances synaptic responses without inducing tonic receptor activation. The compound is soluble in DMSO and is recommended to be stored as a powder at -20°C, protected from light and moisture, where it remains stable for up to three years.
Core Functions:
Active research compound for studying AMPA receptor function in depression, synaptic plasticity, and cognitive disorders
Investigational agent for major depressive disorder, including treatment-resistant depression
Research tool for evaluating AMPA potentiation with reduced risk of convulsive or psychotomimetic side effects
Preclinical and clinical research into cognitive enhancement for working memory and recognition memory
Contact: Tony
Phone: 008618700976396
E-mail: sales@fulecare.com
Whatsapp:008618700976396
Add: Zhang Ba 6 Road,Hi tech zone,Xi'an Shaanxi Province,China
